These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3264903)

  • 1. Serum bactericidal activity against Haemophilus influenzae.
    Gordon DL
    Pathology; 1988 Apr; 20(2):124-9. PubMed ID: 3264903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.
    Tarr PI; Hosea SW; Brown EJ; Schneerson R; Sutton A; Frank MM
    J Immunol; 1982 Apr; 128(4):1772-5. PubMed ID: 6977569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b.
    Steele NP; Munson RS; Granoff DM; Cummins JE; Levine RP
    Infect Immun; 1984 May; 44(2):452-8. PubMed ID: 6609128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against
    Muri L; Schubart A; Thorburn C; Zamurovic N; Holbro T; Kammüller M; Pluschke G; Ispasanie E
    Front Immunol; 2022; 13():1020580. PubMed ID: 36578495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum resistance in an invasive, nontypeable Haemophilus influenzae strain.
    Williams BJ; Morlin G; Valentine N; Smith AL
    Infect Immun; 2001 Feb; 69(2):695-705. PubMed ID: 11159957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring bactericidal antibodies specific for Haemophilus influenzae lipooligosaccharide are present in healthy adult individuals.
    Choi J; Nix EB; Gaultier GN; Cox AD; McCready W; Ulanova M
    Vaccine; 2015 Apr; 33(16):1941-7. PubMed ID: 25738817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins.
    Gnehm HE; Pelton SI; Gulati S; Rice PA
    J Clin Invest; 1985 May; 75(5):1645-58. PubMed ID: 3873475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of complement in the host's defense against Haemophilus influenzae.
    Winkelstein JA; Moxon ER
    J Infect Dis; 1992 Jun; 165 Suppl 1():S62-5. PubMed ID: 1588179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-mediated early clearance of Haemophilus influenzae type b from blood is independent of serum lytic activity.
    Noel GJ; Katz S; Edelson PJ
    J Infect Dis; 1988 Jan; 157(1):85-90. PubMed ID: 3257245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human serum bactericidal activity against Haemophilus influenzae type b.
    Stull TL; Jacobs RF; Haas JE; Roberts MC; Wilson CB; Smith AL
    J Gen Microbiol; 1984 Mar; 130(3):665-72. PubMed ID: 6374030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent otitis media with non-typable Haemophilus influenzae: the role of serum bactericidal antibody.
    Bernstein JM; Faden HS; Loos BG; Murphy TF; Ogra PL
    Int J Pediatr Otorhinolaryngol; 1992 Jan; 23(1):1-13. PubMed ID: 1592547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of serum bactericidal activity following nontypable Haemophilus influenzae acute otitis media.
    Barenkamp SJ; Bodor FF
    Pediatr Infect Dis J; 1990 May; 9(5):333-9. PubMed ID: 2352818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against non-typable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: role of specific antibody and phagocytes.
    Wallace FJ; Witt CS; Clancy RL; Cripps AW
    Immunol Cell Biol; 1995 Jun; 73(3):258-65. PubMed ID: 7590900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic drift of Haemophilus influenzae in patients with chronic obstructive pulmonary disease.
    Groeneveld K; van Alphen L; Voorter C; Eijk PP; Jansen HM; Zanen HC
    Infect Immun; 1989 Oct; 57(10):3038-44. PubMed ID: 2789192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-mediated serum activities against genetically defined capsular transformants of Haemophilus influenzae.
    Swift AJ; Moxon ER; Zwahlen A; Winkelstein JA
    Microb Pathog; 1991 Apr; 10(4):261-9. PubMed ID: 1895927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bactericidal activity and phagocytosis in host defence against Haemophilus ducreyi.
    Lagergård T; Frisk A; Purvèn M; Nilsson LA
    Microb Pathog; 1995 Jan; 18(1):37-51. PubMed ID: 7783597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to serum bactericidal activity distinguishes Brazilian purpuric fever (BPF) case strains of Haemophilus influenzae biogroup aegyptius (H. aegyptius) from non-BPF strains. Brazilian Purpuric Fever Study Group.
    Porto MH; Noel GJ; Edelson PJ
    J Clin Microbiol; 1989 Apr; 27(4):792-4. PubMed ID: 2786003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.